UBS Group’s Celgene Contingent Value Rights CELGZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-6,604
Closed -$4K – 8813
2019
Q3
$4K Buy
6,604
+6,561
+15,258% +$3.66K ﹤0.01% 7603
2019
Q2
$0 Sell
43
-9,543
-100% -$6.85K ﹤0.01% 8516
2019
Q1
$11K Buy
9,586
+9,543
+22,193% +$9.33K ﹤0.01% 6792
2018
Q4
$0 Sell
43
-3,045
-99% -$2.78K ﹤0.01% 8707
2018
Q3
$5K Buy
3,088
+1,989
+181% +$2.64K ﹤0.01% 7541
2018
Q2
$0 Sell
1,099
-8,087
-88% -$2.43K ﹤0.01% 8634
2018
Q1
$3K Buy
9,186
+1,036
+13% +$679 ﹤0.01% 7500
2017
Q4
$8K Buy
8,150
+7,032
+629% +$8.08K ﹤0.01% 7200
2017
Q3
$2K Sell
1,118
-7,338
-87% -$8.97K ﹤0.01% 7538
2017
Q2
$10K Buy
8,456
+5,104
+152% +$5.85K ﹤0.01% 6818
2017
Q1
$4K Sell
3,352
-17,792
-84% -$19.5K ﹤0.01% 7141
2016
Q4
$21K Buy
21,144
+20,686
+4,517% +$23.2K ﹤0.01% 6500
2016
Q3
$0 Buy
458
+415
+965% +$501 ﹤0.01% 8358
2016
Q2
$0 Hold
43
– – ﹤0.01% 8377
2016
Q1
$0 Hold
43
– – ﹤0.01% 8826
2015
Q4
$0 Hold
43
– – ﹤0.01% 8962
2015
Q3
$0 Sell
43
-1,711
-98% -$3.3K ﹤0.01% 9086
2015
Q2
$4K Sell
1,754
-2,812
-62% -$7.2K ﹤0.01% 8036
2015
Q1
$14K Buy
4,566
+4,560
+76,000% +$14.4K ﹤0.01% 7404
2014
Q4
$0 Buy
+6
New +$20 ﹤0.01% 9729

UBS Group's CELGZ Position: Q4 2019 in Review

UBS Group sold out of Celgene Contingent Value Rights (CELGZ) in Q4 2019, closing a stake of 6,604 shares — an estimated $4K sold.

UBS Group first reported a position in CELGZ in Q4 2014 and held it in 20 quarters. The position peaked at $21K in Q4 2016. 0 funds tracked by Wall St. Rank hold CELGZ as of Q4 2019.

  • UBS Group reported no remaining Celgene Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
  • UBS Group sold 6,604 Celgene Contingent Value Rights shares in Q4 2019, an estimated $4K.
  • UBS Group first reported a position in Celgene Contingent Value Rights in Q4 2014 and held it in 20 quarters.
  • UBS Group's Celgene Contingent Value Rights position peaked at $21K in Q4 2016.
  • 0 funds tracked by Wall St. Rank held Celgene Contingent Value Rights as of Q4 2019.

Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.